You have 1 action to finish to complete your account. Craft your experience by picking your interest on the Personalisation Page
Type 2 Inflammation
On demand events

ADVENT at 25th World Congress of Dermatology, WCD 2023 Highlights

See highlights of ADVENT symposia at WCD congress 2023 

Stephan Weidinger
Amy Paller
Lisa Beck
MD, PhD
Stephan Weidinger +5 more

Learning objectives

  • Examine the challenges faced by dermatologists when managing moderate-to-severe atopic dermatitis in children (<12 years)
  • Explore the relevance of targeting type 2 inflammation and the implications for disease course modification in childhood
  • Review emerging data on treatment options and practical management of children with moderate-to-severe AD
  • Recognize that atopic dermatitis and prurigo nodularis are distinct diseases with commonalities and differences in clinical and pathophysiological characteristics
  • Review barrier dysfunction in atopic dermatitis and share evidence supporting skin barrier normalization achieved by inhibiting type 2 cytokines
  • Review the role of type 2 cytokines in dermal fibrosis and pruritus in prurigo nodularis

Description

Watch the key highlights from two ADVENT symposia held at WCD 2023. In the first symposium, entitled “IL-4 and IL-13: Shared and Unique Roles in Atopic Dermatitis (AD) and Prurigo Nodularis (PN)”, Dr. Mark Tang, Prof. Lisa Beck, and Prof. Gil Yosipovitch discussed the similarities and differences between AD and PN. In the second symposium, entitled “Atopic Dermatitis (AD) in Children: Early Intervention Can Reduce Long-term Disease Impact”, Professors Mark Koh, Stephan Weidinger, Amy Paller, and Elaine Siegfried explored the challenges faced by dermatologists when managing moderate-to-severe AD in children (<12 years old) and discussed how targeting type 2 inflammation may influence disease course. 

MAT-GLB-2304276 V2 08/2023

About these experts